Trial · NCT06480864
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
NCT06480864, Not applicable, Recruiting, Yunpeng Liu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer. Trials, record NCT06480864. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06480864
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
- NCT number
- NCT06480864
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 38 participants, estimated
- Lead sponsor
- Yunpeng Liu
- Conditions
- Small Cell Lung Cancer
- Interventions
- Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin, Cisplatin, Etoposide
- First posted
- 2024-06-28
- Last updated
- 2025-01-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | baseline up to approximately 6 month | To evaluate the efficacy of anti-tumor by Resist1.1 (In months) |
| Secondary | Objective response rate (ORR) | baseline up to approximately 6 month | To evaluate the efficacy of anti-tumor by Resist1.1 (In percent) |
| Secondary | Disease control rate (DCR) | baseline up to approximately 6 month | To evaluate the efficacy of anti-tumor by Resist1.1(In percent) |
| Secondary | Duration of Response (DOR) | baseline up to approximately 12 months | To evaluate the efficacy of anti-tumor by Resist1.1(In months) |
| Secondary | Overall survival (OS) | baseline up to approximately 12 month | To evaluate the efficacy of anti-tumor by Resist1.1(In months) |
| Secondary | Second progression-free survival (PFS2) | baseline up to approximately 12 months | To evaluate the efficacy of anti-tumor by Resist1.1(In months) |
| Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | From the initiation of the first dose to 28 days after the last dose | To identify the incidence of AE and SAE in clinical trial |
| Other | Correlation of biomarkers and tumour response | baseline up to approximately 12 months | Biomarkers Include: haematopoietic factors in pg/mL (IL-6,IL-8, IL-10, etc.), PD-L1 expression in TPS, T-cell subsets in percent, T-cell immunoprecision typing and regulatory T-cell counts in percent. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06480864
GET https://conductscience.org/api/trials/v1/NCT06480864/registered